2009.09.19 – How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis

Posted in Cancer, Cancer Research, Leukemia on 09/19/2009 04:56 am by admin

How do JAK2-inhibitors work in myelofibrosis: An alternative hypothesis

The latest in leukemia news & blogs from http://www.lrjournal.com/current.rss

Abstract: The clinical efficacy of JAK2-inhibitors in patients with myelofibrosis, that involves a rapid and massive reduction of spleen enlargement and improvement of clinical symptoms, is not accompanied by significant modifications of hematologic parameters nor of the burden of JAK2V617F allele. Furthermore, clinical improvement has been reported to occur irrespective of patient’s JAK2-mutated status. On the other hand, dramatic changes in plasma cytokine levels have been observed. Based on available information about the role of cytokines in the pathogenesis of myelofibrosis, the hypothesis that the clinical efficacy of JAK2-inhibitors could be mainly ascribed to a general down-regulation of cytokine production and cytokine signaling is discussed.


Bookmark and Share